The head of the ARPM, the chairman of the Public Council under the Federal Service for Surveillance in Healthcare (Roszdravnadzor) Victor Dmitriev took part in a meeting of the Expert Council of the Health Protection Committee on the topic «State procurement of medicinal products. Increasing budget efficiency and sustainability of drug provision for patients», during which he drew attention to the need to «improve» the «second extra» regulation by strictly spelling out all the mechanisms for forming the list of strategically important drugs, creating a clear and distinct traceability system, supporting bona fide domestic manufacturers and ensuring the observance of patients’ rights to choose high-quality, effective and affordable therapy. He emphasized that the launch of the traceability system is possible only when the regulatory framework is fully prepared and the level of technical support serves as a guarantee of transparency and uninterrupted operation of the system. Today this is not the case! This means that there is a risk that a drug from a bona fide manufacturer, produced in a full cycle, may turn out to be «extra».